Rachel R. Bailey, MPH

Articles by Rachel R. Bailey, MPH

Economic Model for Emergency Use Authorization of Intravenous Peramivir

ByBruce Y. Lee, MD, MBA,Julie H. Y. Tai, MD,Rachel R. Bailey, MPH,Sarah M. McGlone, MPH,Ann E. Wiringa, MPH,Shanta M. Zimmer, MD,Kenneth J. Smith, MD, MS,Richard K. Zimmerman, MD, MPH

March 10th 2011

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

Economic Model for Emergency Use Authorization of Intravenous Peramivir

ByBruce Y. Lee, MD, MBA,Julie H. Y. Tai, MD,Rachel R. Bailey, MPH,Sarah M. McGlone, MPH,Ann E. Wiringa, MPH,Shanta M. Zimmer, MD,Kenneth J. Smith, MD, MS,Richard K. Zimmerman, MD, MPH

January 14th 2011

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

Screening Cardiac Surgery Patients for MRSA: An Economic Computer Model

ByBruce Y. Lee, MD, MBA,Ann E. Wiringa, MPH,Rachel R. Bailey, MPH,Vishal Goyal, MPH,G. Jonathan Lewis, DO, MPH,Becky Y. K. Tsui, MPH,Kenneth J. Smith, MD, MS,Robert R. Muder, MD

July 13th 2010

Routine preoperative MRSA screening of cardiac surgery patients could provide substantial economic value to third-party payers and hospitals under a wide range of circumstances.

Economics of Influenza Vaccine Administration Timing for Children

ByBruce Y. Lee, MD, MBA,Julie H. Y. Tai, MD,Rachel R. Bailey, MPH,Kenneth J. Smith, MD, MS,Andrew J. Nowalk, MD, PhD

March 1st 2010

Vaccinating children earlier (ie, September or October) can provide net economic benefit to society and to third-party payers. Vaccination of children remained cost-effective through December.